WO2015137652A1 - Huile de graines fermentées de camellia japonica inhibant la 5-alpha réductase permettant d'atténuer une hypertrophie bénigne de la prostate et la calvitie - Google Patents

Huile de graines fermentées de camellia japonica inhibant la 5-alpha réductase permettant d'atténuer une hypertrophie bénigne de la prostate et la calvitie Download PDF

Info

Publication number
WO2015137652A1
WO2015137652A1 PCT/KR2015/001925 KR2015001925W WO2015137652A1 WO 2015137652 A1 WO2015137652 A1 WO 2015137652A1 KR 2015001925 W KR2015001925 W KR 2015001925W WO 2015137652 A1 WO2015137652 A1 WO 2015137652A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
fermented
fermentation
enzyme
camellia oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2015/001925
Other languages
English (en)
Korean (ko)
Inventor
정종문
이승숙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
COSBEN Co Ltd
Bens Lab Co Ltd
Original Assignee
COSBEN Co Ltd
Bens Lab Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by COSBEN Co Ltd, Bens Lab Co Ltd filed Critical COSBEN Co Ltd
Publication of WO2015137652A1 publication Critical patent/WO2015137652A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6418—Fatty acids by hydrolysis of fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine

Definitions

  • the present invention relates to functional foods, pharmaceutical compositions and cosmetic raw materials for inhibiting 5-alpha reductase to improve and prevent prostatic hypertrophy and hair loss, and more particularly, essential unsaturated fatty acids including free oleic acid.
  • the present invention relates to functional foods, pharmaceutical compositions, and cosmetic raw materials for preventing and treating enlarged prostate, and for preventing and improving hair loss, including fermented natural oil including abundant fermented camellia oil (Camellia japonica seed oil) as an active ingredient.
  • the prostate is an accessory gonad consisting of gland tissue and fibrous muscle tissue.
  • the prostate gland produces and secretes semen and is located just below the bladder and surrounds the urethra.
  • the function of the prostate is reported to be responsible for about 40% of semen and play an important role in the survival and activity of sperm.
  • the prostate provides sperm with nutrients, maintains proper ionic concentration and acidity, and contains zinc to prevent bacterial infection.
  • BPH prostatic hyperplasia
  • Prostate hyperplasia is an abnormally enlarged prostate gland that blocks the passage of urine below the bladder or compresses the urethra to prevent urine from draining smoothly and pushes up the bladder to cause urinating more than eight times a day, night urinary, strong and sudden urination
  • Bladder storage symptoms such as urinary urinary urge, delayed urine (the urine comes out of urine when urine is seen), and urinary urine (a break in urine flow)
  • the lower urinary tract symptoms are referred to collectively as symptoms that indicate the discharge of the bladder, such as the need to give strength during urination.
  • prostate hyperplasia increases and prostate enlargement occurs in more than 50% of men over 60 and in 90% of men over 85.
  • Prostate hypertrophy occurs mainly in men over 40 who have normal testicles that make androgen, and one of the most important causes is the correlation between testosterone conversion and aging.
  • DHT dihydrotestosterone
  • testosterone levels are gradually lowered but more prostatic hyperplasia occurs. This is due to the dihydrotestosterone, which increases the number of cells in this prostate.
  • Male hormone is present in two forms, testosterone and dihydrotestosterone, which are more important for prostate growth.
  • testosterone and dihydrotestosterone bind to the same male hormone receptor in a similar proportion in the prostate, most male hormone receptors in the prostate are more dehydro than testosterone because the dihydrotestosterone-male hormone receptor complex is more stable than the testosterone-male hormone receptor complex. It will remain in combination with testosterone.
  • dihydrotestosterone does not decrease significantly with age, increasing the androgen receptors of prostate cells to maintain the endocrine balance and eventually stimulate other growth factors that lead to prostate proliferation as they age. Prostate enlargement will occur.
  • 5-alpha-reductase which converts testosterone to dihydrotestosterone
  • 5-alpha reductase is a microsome's NADPH dependent 3-oxo-5 ⁇ -steroid-dehydrogenase that reduces double-linked steroids such as testosterone.
  • the enzyme is involved in bile acid synthesis and metabolism of androgen and estrogen in the body.
  • 5-alpha reductase has type 1, type 2, and type 3 subtypes. Type 1 is present in various organs such as skin and liver tissue. Type 2 is mainly present in the urinary tract including the liver and prostate.
  • Testosterone is converted to dihydrotestosterone by at least 90% by 5-alpha reductase in prostate tissue and dihydrotestosterone promotes prostate growth with approximately 10 times more activity than testosterone. Therefore, the efficient inhibition of 5-alpha reductase may reduce the synthesis of physiologically active dihydrotestosterone, which may eventually improve or treat prostatic hyperplasia.
  • the number of human hair is estimated to be about 100,000 to 150,000. Hair falls from 50 to 100 hairs a day, and hair loss begins when more than 100 hairs fall out a day.
  • the causes of hair loss are many and vary from person to person. Men's hair in particular tends to become thinner at the peak of their 20s.
  • Male pattern baldness (MPB) the most common of the various symptoms of hair loss, has a large genetic characteristic. Another major reason is that male hair abnormalities cause inflammation of the scalp due to weak hair roots and excessive sebum secretion. This falls out.
  • the most common cause of masculine alopecia is an abnormality of androgen alopecia.
  • over-synthesis of dihydrotestosterone by 5-alpha reductase causes dihydrotestosterone to bind to androgen receptors around the hair follicles, shrinking and devastating the hair follicles and eventually reducing the hair growth period.
  • the roots of the hair, the hair roots do not develop sufficiently and at the same time there is not enough pigment accumulation. This immature hairless power often comes out of the scalp and eventually begins to lose hair. Continued hair follicles eventually die and permanent hair loss occurs, which makes it difficult to treat other than hair transplantation.
  • Dihydrotestosterone provides the factors that make the hair shorter and longer during the growth cycle of the hair and eventually make the hair smaller and smaller as the growth cycle continues.
  • the hair follicles contract and instead, the sebaceous glands become larger and the hair becomes thinner and smaller, usually oily, causing rashes or sores.
  • the thinner head turns into a downy hair and becomes invisible to our eyes, and the scalp inside the head begins to look into it.
  • the hair follicles will die forever and no remedy will ever recover.
  • testosterone primarily affects the growth of armpit hair and pubic hair
  • dehydrotestosterone is known to affect beards and baldness, but it is not clear.
  • Inhibitors of 5-alpha reductase synthesis include Finasteride and Dutasteride. Testosterone is converted to dihydrotestosterone by 5-alpha reductase in prostate tissue. Therefore, taking a 5-alpha reductase inhibitor that effectively blocks the conversion of dihydrotestosterone can reduce the size of the prostate gland. After six months of use, it is known that the size of the prostate is reduced to the maximum. Finasteride, a competitive inhibitor of 5-alpha reductase, developed by Merck, also inhibits type 1 but mainly reduces type 2 5-alpha reductase, reducing dihydrotestosterone in the prostate and blood.
  • Dutasteride has a longer half-life than Finasteride, and is 45 times stronger for type 1 enzymes and 2.5 times stronger for type 2 enzymes. Most of the metabolism in the liver, hepatic failure should be limited to use. Synthetic inhibitors of these 5-alpha reductases can be regarded as a fundamental treatment for prostatic hyperplasia, but patients who take 5 mg / day for 4 to 6 months for long periods of time will be effective. . Side effects include erectile dysfunction, decreased libido, gynecomastia, and ejaculation disorders.
  • Finasteride is also used to treat androgenetic alopecia. Finasteride was first used to treat prostatic hyperplasia, but has been recognized by the US Food and Drug Administration to treat hair loss at a daily dose of 1 mg per day. As mentioned above, this drug also has a hair loss treatment effect through the mechanism of inhibiting 5-alpha reductase present in the scalp. However, at least 3-5 months is effective, and if you stop taking it back to its original condition within 12 months. In addition, because the structure of finasteride itself is similar to sex hormones such as testosterone and progesterone hormones, side effects are often found in women, and in particular, strictly limit the use of mothers. Even factories producing finasterides prevent women from participating directly in production.
  • Minoxidil was also developed for the treatment of hypertension and observed to inhibit hair loss in hypertensive patients.
  • the mechanism of action of minoxidil is not clear, but it can be seen to facilitate the production and development of hair by expanding the blood vessels of the scalp and easily supplying oxygen and nutrients to the hair follicles.
  • Saw palmetto reported to be used by more than 2 million people in the United States alone, is an extract from the fruit of the saw palm tree and is a representative natural-derived functional food most commonly used for prostatic hyperplasia.
  • Indians have used saw palmetto fruit as a remedy for the genitourinary system.
  • the main components of saw palmetto are TG-type fatty acids and phytosterols, which act as 5-alpha reductase inhibitors to improve prostate hyperplasia and hair loss.
  • saw palmetto has been recognized as effective in improving prostate hyperplasia and is now marketed as an individually recognized product. Recently, it is produced and sold as a therapeutic agent for enlarged prostate by using coucurbite seed oil as an active ingredient.
  • this seed oil is an European pumpkin seed extract and is imported from European pharmaceutical companies.
  • pharmaceutical companies explain that coucurbite seed oil suppresses blood cholesterol causing prostatic hypertrophy and prevents changes in male hormones to treat urination disorder caused by hypertrophy.
  • Camellia is also called winter rose and grows in Shandongzhou of China, Taiwan, South Korea, Japan, etc. It grows mainly at 300-1,100m above sea level and is usually 1.5-6m in height. Flowers bloom from January to March. In Korea, it is grown on Tongyeong and Jeju Island.
  • camellia oil which is produced in Tongyeong, is imported from Japan and specialized in atopic dermatitis.
  • Camellia oil is a fatty oil derived from the seeds of Camellia japonica L. of theaceae and its related plants. The fatty acid is similar to olive oil and contains up to 82-86% of oleic acid. Similar uses are used in creams, emulsions, etc., especially for hair.
  • Oleic acid which is found in camellia oil, lowers LDL cholesterol, a low-density cholesterol that is harmful to the body, while raising high levels of HDL cholesterol, a high-density cholesterol that is good for the body, preventing high blood pressure and heart disease. It is known to be effective in preventing cancer and reducing memory due to aging.
  • oleic acid In nature, however, it does not exist as free oleic acid, but is usually covalently attached to glycerol in ester form.
  • Commercial oleic acid is either K + or Na + attached to the saponification of oil, ethyl ester form by ethanolysis, or manufactured through several industrial processes.
  • essential fatty acids including oleic acid and linoleic acid which are free from glycerol skeletal molecules, are fermented to facilitate absorption and use of camellia oil containing abundant essential fatty acids oleic acid and linoleic acid for easy absorption and use.
  • the present invention was completed by preparing a fermented natural oil having the effect of preventing and improving prostatic hyperplasia and male hair loss by increasing the content of 5-alpha reductase.
  • an object of the present invention is to select a microbial strain having a high function of lipase that removes essential unsaturated fatty acids from glycerol skeletal molecules of camellia oil and incubate it in a lipase-induced medium, the culture medium containing a high titer of lipase is ammonium sulfate Precipitates, concentrates and dialysates enzyme proteins to eliminate various metabolic final substances that may occur during microbial cultivation and contaminate the final fermented product, and eliminates the fermentation odor produced by direct fermentation. Ferment the camellia oil using lipase concentrated fermentation solution to block the source.
  • an object of the present invention is to produce a fermented natural oil for oral use for the enlargement of the prostate gland, and for oral and skin application for the prevention and treatment of hair loss to have a synergistic effect.
  • the present invention provides a fermented camellia oil containing abundant essential fatty acids, including oleic acid by fermenting camellia oil.
  • the present invention also provides a method for producing fermented camellia oil comprising the step of fermenting from a camellia oil using a fermentation enzyme or fermentation enzyme composition.
  • the present invention is fermented vegetable oil containing one or more of olive oil, canola oil, olive oil, rapeseed oil, moringa oil or sunflower seed oil in addition to camellia oil, and contains abundant essential essential fatty acids such as oleic acid.
  • canola oil olive oil
  • rapeseed oil moringa oil or sunflower seed oil in addition to camellia oil
  • sunflower seed oil contains abundant essential essential fatty acids such as oleic acid.
  • the present invention also provides a method for producing fermented natural oil comprising the step of fermenting using a fermentation enzyme or fermentation enzyme composition from the various vegetable oils.
  • the present invention provides a pharmaceutical composition or health functional food that inhibits 5-alpha reductase, improves and prevents prostatic hypertrophy and hair loss by using fermented camellia oil containing abundant essential fatty acids as an active ingredient.
  • the present invention provides a skin external preparation, cosmetic composition, or other quasi-drugs to inhibit 5-alpha reductase, improve and prevent hair loss by using fermented camellia oil containing abundant essential fatty acids as an active ingredient.
  • the present invention provides a pharmaceutical composition or a health functional food that inhibits 5-alpha reductase, improves and prevents prostatic hypertrophy and hair loss by using a fermented natural oil containing abundant essential fatty acids as an active ingredient.
  • the present invention provides a skin external preparation, cosmetic composition, or other quasi-drugs for inhibiting 5-alpha reductase, improving and preventing prostatic hypertrophy and hair loss by using fermented natural oil containing abundant essential fatty acids as an active ingredient. .
  • fermented camellia oil contains a large amount of essential fatty acids including oleic acid as compared to other pre-fermentation oils and shows an effective effect.
  • the microorganism producing lipase is first induced in culture, and then the culture medium containing the lipase is precipitated, concentrated and dialyzed using ammonium sulfate to physically emulsify the fermentation broth and camellia oil of high titer. After mixing, the fermentation process is carried out under optimum conditions, which can eliminate microbial waste contamination and odors peculiar to direct fermentation. The production efficiency of free unsaturated fatty acids can be greatly improved.
  • fermented camellia oil has the ability to inhibit 5-alpha reductase to lower blood dihydrotestosterone (dihydrotestosterone) to treat, improve or prevent the enlarged prostate.
  • rich free essential fatty acids containing fermented camellia oil have the effect of preventing or improving male hair loss by inhibiting 5-alpha reductase.
  • 1 is a graph showing the results of analyzing the prostate weight reduction effect of fermented camellia oil.
  • Figure 2 is a graph showing the results of analyzing the inhibitory effect of 5-alpha reductase of fermented camellia oil.
  • FIG. 3 is a graph showing the results of analyzing the growth promoting effect of the fermented camellia oil.
  • Figure 4 is a graph showing the results of measuring the cytotoxicity of mouse-derived macrophages of fermented camellia oil.
  • Figure 5 is a graph showing the results of measuring the long-term weight change of female mice according to a single toxicity test for fermented camellia oil mice.
  • Figure 6 is a graph showing the results of measuring the long-term weight change of male mice according to a single toxicity test for fermented camellia oil mice.
  • Figure 7 is a graph showing the results of measuring the weight change of female and male mice according to a single toxicity test for fermented camellia oil mice.
  • the present invention fermented camellia oil to provide a fermented camellia oil containing abundant essential fatty acids, including oleic acid.
  • the present invention provides a fermented camellia oil containing fermented camellia oil in abundance.
  • Camellia japonica seed oil is known as Camellia japonica seed oil, and the raw material is fat oil obtained from seed removed from Camellia japonica Linne ( Theaceae ). Extraction and manufacturing methods of camellia oil include cold pressing obtained by pressing at room temperature, heat extraction by pressing at high temperature, and solvent extraction using ethanol or hexane at high temperature and high pressure. extraction methods. Camellia oil contains 80% or more of oleic acid and contains palmitic acid, linoleic acid and linolenic acid. It has good skin absorption and has a soothing effect. In addition, it is known to inhibit the growth of Staphylococcus aureus and is effective in atopic dermatitis, skin itching and the like.
  • the active ingredient of fermented camellia oil used in the present invention refers to an essential unsaturated fatty acid, especially an oil containing a large amount of oleic acid.
  • the essential fatty acid preferably contains a large amount of free oleic acid, linoleic acid, gamma linolenic acid and the like.
  • the fermented camellia oil containing a large amount of free essential fatty acids is preferably effective to inhibit the 5-alpha reductase.
  • the oleic acid does not readily oxidize and produce lipid peroxides compared to other fatty acids.
  • Oleic acid is known to prevent arteriosclerosis and heart disease by removing LDL-cholesterol in the blood like linoleic acid and alpha-linolenic acid. It is also the most abundant fatty acid in breast milk, helping the baby grow and develop.
  • the fermentation enzyme is preferably a lipase derived from the genus Rizopus or Candida, or a fermentation enzyme concentrate for fermentation of natural plants concentrated through extraction, ammonium sulfate, and dialysis in plants and animals.
  • the present invention also provides a method for preparing fermented camellia oil.
  • Fermented camellia oil used in the present invention can be prepared as follows.
  • a method of preparing fermented camellia oil for achieving the purpose is obtained by separating fatty acids from glycerol, which is a skeletal molecule constituting oil, using a fermentation concentrate containing lipase produced by microorganisms. Fermentation results in a richer free essential fatty acid content than before fermentation.
  • microbial culture a strain that produces large amounts of lipase, is added directly to the oil, and a small amount of artificial emulsifier is added to emulsify the oil so that it can be easily fermented. Add various nutrients for this and incubate it for a long time under optimum conditions. At the end of the incubation, centrifugation is usually performed to separate the microbial cells and the oil culture.
  • the microbial direct fermentation oil thus produced usually has a characteristic smell of microbial fermentation, and it is troublesome to separate cultured microorganisms from fermentation oils. It is also likely that the final fermented oil product is contaminated.
  • the final fermentation oil must be passed through the adsorption column or a distillation or filtration process must be added to remove odors and contaminants.
  • the high fat-soluble substance as a compound that is released as the microorganism grows is easily contaminated with the final fermentation oil, and it is difficult to remove it later from the fermentation oil.
  • the fermentation microorganisms are pre-cultured in a lipase-inducing medium, and then only the culture medium is recovered and concentrated, and then emulsified and fermented by the high titer of lipase-containing culture solution and oil by physical method.
  • Fifth there is no contamination of chemicals that can make an unfavorable impression.
  • Fifth it is possible to produce the maximum amount of essential unsaturated fatty acids freed in the most natural way, thus increasing competitiveness over other fermented products.
  • Fermentase used in the present invention is preferably a lipase (Lipase), the fermentation enzyme composition is preferably a composition comprising a lipase, in particular, pre-cultivation of microorganisms capable of producing lipase and enrich the enzyme filtrate obtained One is preferable.
  • Lipases derived from plants or animals can be included in the preparation of the present invention, without being limited to lipase fermentation concentrates derived from microorganisms.
  • the method for preparing fermented camellia oil used in the present invention comprises the steps of: i) mixing the fermented enzyme or fermented enzyme composition in a weight ratio of 1: 8 to 8: 1 in camellia oil; ii) blending the mixture of step i) in a blender for 5-10 minutes and then physically emulsifying by sonicating for 30-60 minutes; iii) fermenting the mixture of step ii) with mixing at 300-400 rpm for fermentation temperature of 25-45 degrees Celsius, pH 5.0-8.0 and fermentation time 48-120 hours; And iv) separating the fermentation oil from the fermentation concentrate by centrifugation and ultrafiltration of the fermentation product of step iii).
  • Method for producing a fermentation enzyme used in the present invention comprises the steps of a) culturing a microorganism (including genus lypus or Candida microorganisms) under specific induction conditions to obtain a fermentation broth with a large amount of lipase enzyme added to a high titer; b) concentrating and dialysis the enzyme filtrate obtained from the culture; c) adding the microbial fermentation broth and vegetable oil and fermenting at optimum conditions (physical emulsification, optimal pH, optimal temperature, optimal mixing rpm and fermentation time); And d) recovering the fermented oil.
  • a microorganism including genus lypus or Candida microorganisms
  • step a) is a step of incubating the microorganisms to produce as much as possible a high titer of primary lipase under aerobic conditions.
  • step b) is a step of separating the cells from the culture medium after the primary culture and concentrated dialysis of the enzyme.
  • each cultured strain culture was centrifuged at 4 °C, 10,000 rpm conditions to isolate the cells from the culture medium, the supernatant was treated with ammonium sulfate at 4 °C to precipitate proteins
  • the concentrated enzyme can be dissolved in pH 7.0 (sodium phosphate buffer, 50 mM) and dialyzed in the same buffer to obtain a concentrated lipase.
  • step c) is a step of fermentation by adding the obtained lipase concentrated solution and vegetable oil.
  • the temperature of the oil is preferably 40 ° C.
  • the pH of the fermentation enzyme solution to be added is preferably pH 7.0.
  • the mixing ratio of the vegetable oil and the fermented enzyme solution is preferably a ratio of 50% by weight of vegetable oil to 50% by weight of the fermented enzyme solution.
  • the fermentation time is preferably 120 hours.
  • 40 degreeC is preferable. This is because the lipase and the vegetable natural oil must be fermented enough to allow the production of the free essential fatty acids.
  • the present invention also fertilizes vegetable oils including one or more of olive oil, canola oil, olive oil, rapeseed oil, moringa oil or sunflower seed oil in addition to camellia oil to enrich free essential fatty acids such as oleic acid. It provides fermented natural oil containing.
  • the essential fatty acid contains a large amount of free oleic acid, linoleic acid or gamma linolenic acid, and the fermented camellia oil containing a large amount of the free essential fatty acid is preferably effective to inhibit the 5-alpha reductase.
  • the present invention is a glass such as oleic acid comprising the step of fermenting one or more of olive oil, canola oil, olive oil, rapeseed oil, moringa oil or sunflower seed oil by treating the fermentation enzyme or fermentation enzyme composition It provides a method for producing a fermented natural oil containing abundant essential fatty acids.
  • the present invention also provides a pharmaceutical composition for the prevention and treatment of enlarged prostate, containing fermented camellia oil according to the present invention, and a dietary supplement, cosmetic composition or quasi-drug for preventing and improving prostatic hyperplasia.
  • compositions are based on fermented camellia oil as a main ingredient and may comprise as an additional ingredient a combination selected from a pharmaceutically, food or cosmetically acceptable carrier such as vitamins and the like.
  • compositions may further contain one or more active ingredients which exhibit the same or similar function in addition to the above ingredients.
  • the composition is not limited to camellia oil but may include a vegetable oil containing a large amount of oleic acid or linoleic acid in essential fatty acids. This may include olive oil, canola oil, rapeseed oil, sunflower seed oil, pecan oil, tea tree oil, and the like. When fermented to include a large amount of free essential unsaturated fatty acids can have a similar effect to fermented camellia oil.
  • compositions may be formulated in a variety of oral and parenteral formulations, which may be formulated using conventional diluents or excipients, such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, and the like.
  • Dosages of such compositions vary depending on the patient's weight, age, sex, health condition, diet, time of administration, method of administration, rate of excretion and severity of the disease, with the daily dosage being approximately based on the amount of the composition. It may be from 0.0001 to 10 g / kg, may be administered 1 to 6 times a day.
  • the composition for treating, improving and preventing prostatic hyperplasia is to effectively inhibit 5-alpha reductase to improve prostatic hyperplasia by dihydrotestosterone (dihydrotestosterone) made by excess of 5-alpha reductase or It means treatment and prevention, and its clinical effect means restoring the enlarged prostate to normal size due to enlargement of the prostate.
  • the present invention provides a pharmaceutical composition for preventing and treating hair loss, and a health functional food, cosmetic composition or quasi-drug for preventing and improving hair loss, containing fermented camellia oil as an active ingredient according to the present invention.
  • compositions are based on fermented camellia oil as a main ingredient and may comprise as an additional ingredient a combination selected from a pharmaceutically, food or cosmetically acceptable carrier such as vitamins and the like.
  • the composition is not limited to camellia oil but may include a vegetable oil containing a large amount of oleic acid or linoleic acid in essential fatty acids. This may include olive oil, canola oil, rapeseed oil, sunflower seed oil, pecan oil, tea tree oil, and the like. When fermented to include a large amount of free essential unsaturated fatty acids can have a similar effect to fermented camellia oil.
  • compositions may be formulated in a variety of oral and parenteral formulations, which may be formulated using conventional diluents or excipients, such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, and the like.
  • Dosages of such compositions vary depending on the patient's weight, age, sex, health condition, diet, time of administration, method of administration, rate of excretion and severity of the disease, with the daily dosage being approximately based on the amount of the composition. It may be from 0.0001 to 10 g / kg, may be administered 1 to 6 times a day.
  • the pharmaceutical composition for treating, improving and preventing hair loss refers to male hair loss caused by dihydrotestosterone, which is excessively produced by 5-alpha reductase by effectively inhibiting 5-alpha reductase. Means to improve, treat, and prevent hair loss when the composition is orally administered or applied directly to the scalp.
  • the present invention means that the fermented camellia oil is quickly absorbed into the scalp by using it for cosmetic compositions or coatings to have a more effective male-type hair loss improving effect.
  • the present invention is fermented vegetable oil containing one or more of olive oil, canola oil, olive oil, rapeseed oil, moringa oil or sunflower seed oil in addition to camellia oil, and contains abundant essential essential fatty acids such as oleic acid.
  • a pharmaceutical composition for preventing and treating prostatic hyperplasia which contains fermented natural oil as an active ingredient, and a dietary supplement, cosmetic composition, or quasi-drug for preventing and improving prostatic hyperplasia.
  • the present invention is fermented vegetable oil containing one or more of olive oil, canola oil, olive oil, rapeseed oil, moringa oil or sunflower seed oil in addition to camellia oil, and contains abundant essential essential fatty acids such as oleic acid.
  • the present invention provides a pharmaceutical composition for preventing and treating hair loss, and a dietary supplement, cosmetic composition, or quasi-drug for preventing and improving hair loss.
  • Candida rugosa or other Candida microorganism culture medium that produces lipase for fermenting camellia oil contains 2% olive oil, 0.3% yeast extract, 0.3% malt extract, 0.5 A composition of% peptone, 1% dextrose was used, incubated at pH 7.0, 30 degrees Celsius, and culture medium of Rizopus oryzae or other Rizopus microbial culture was 2% olive oil. , 4% potato starch, 1% dextrose composition was used, was cultured at pH 6.0, 30 degrees Celsius was used to prepare a high titer fermentation concentrate with a large amount of lipase production secretion.
  • the culture time of the microorganism was cultured for 70-90 hours in the case of Candida strain, and 100-120 hours in the case of Rizopus strain.
  • the microbial culture was terminated, the microbial cells were allowed to settle by centrifugation at 8,000 rpm, and only the supernatant was recovered. Then, 60-80% ammonium sulfate was added slowly at 4 degrees Celsius to stir the proteins in the culture medium.
  • the precipitated enzyme protein was centrifuged at 12,000 rpm at 4 degrees Celsius to settle and remove the supernatant, and then dissolved in 50 mM sodium phosphate buffer (pH 7.0). This concentrated enzyme protein was repeatedly dialyzed 2-4 times at 4 degrees Celsius with the same buffer to remove substances with low molecular weight.
  • the produced free fatty acid was dissolved by adding 2.5 ml of isooctane, and 1 ml of copper-acetate-pyridine was added to develop a copper reaction. At this time, the degree of color development was measured for absorbance at 715nm.
  • the lipolytic activity of lipase was expressed in units of units and 1 unit was defined as 1 ⁇ mol of the fatty acids produced.
  • the temperature of camellia oil was set to 37 ° C, and the fermented enzyme solution produced by microbial culture and highly concentrated was dialyzed in sodium phosphate buffer (50 mM) at pH 7.0. After mixing and using each other. That is, after mixing at a ratio of 50% by weight of oil to 50% by weight of the highly concentrated fermentation enzyme solution (including lipase), blended in a blender for 10 minutes and then sonicated for 30 minutes to complete the physical emulsification process, the rotation speed 350 rpm, Fermentation was carried out at 37 °C for 72 hours. After fermentation, the oil was centrifuged at 10,000 rpm for 20 minutes to separate the fermentation enzyme solution and the enzyme residue, followed by ultrafiltration to obtain only fermented natural oil.
  • sodium phosphate buffer 50 mM
  • Canola oil fermented in the same manner as in ⁇ Example 2> was obtained.
  • Essential fatty acid content was determined using HPLC. At this time, in order to quantify the content of each essential fatty acid, a standard reagent for each fatty acid was obtained, a standard curve was first obtained by HPLC, and fermented camellia oil was analyzed and compared with the standard curve.
  • HPLC column C18,250 x 4.6 mm ID
  • the mobile phase was mixed with 0.005% TFA in acetonitrile: 0.005% TFA in water in a volume ratio of 8: 2 with a flow rate of 1.0 ml / min.
  • the sample injection amount was used 0.01 ml and measured at a wavelength of UV 210 nm.
  • the slope of the mobile phase was started at 20:80 (v / v) and maintained for 30 minutes, after which the fatty acids were analyzed with increasing polarity.
  • Table 3 Shown in Table 3 below shows the content of fatty acids described in the certificate of camellia oil (Tongyeong, Korea), canola oil (Quebec, Canada), olive oil (greek acid) used for the present invention. These fatty acids are more than 99% ester-bonded to glycerol backbone molecules and the total content of free fatty acids is less than 1%.
  • the animals to be used for the experiment were the following experiments using 260-300g 7-week-old male Sprague Dawley rats (Semtaco, Osan, Korea). The rats were allowed to acclimate for one week, and the rats were tested under conditions of 18-22 degrees Celsius, 40-50% humidity, 12 hours dark and 12 hours bright. In the comparison group, finasteride was used to treat prostatic hypertrophy.
  • the male SD rats except for the normal group were anesthetized with ether, and then the abdominal medial incision was made through the abdominal cavity, and the testicles were placed into the abdominal cavity. The testicles were fixed to the side abdominal wall.
  • the group of each individual was administered the composition according to the present invention (fermented camellia oil) after the induction of prostate hypertrophy by hormonal stimulation (control), prostate hypertrophy by hormonal stimulation.
  • the comparison group administered with finasteride after prostate hypertrophy induced by hormone stimulation and the experimental group 2 administered the composition (fermented camellia oil) of the present invention to confirm the other effects and toxicity of the composition.
  • Each group was assigned the same weight of six dogs in each group based on weight, and propionate testosterone (TP) is injected subcutaneously at 5 mg / kg / day for three weeks and the composition of the present invention
  • TP propionate testosterone
  • the control group was orally administered 2 mg / kg / day for 3 weeks.
  • 5-alpha reductase inhibitory effect was performed according to Hirosumi's method.
  • 40 mM potassuim phosphate, 0.2 mM NADPH buffer solution was mixed with the enzyme and the fermented camellia oil sample prepared in Example 2, 1 mM DTT, and 120 nCi [1.2.6.7-3H] T. After adjusting to 500 ⁇ l and mixing well, it was reacted at 37 °C 60 minutes. Then, 1 ml of ethyl acetate was added to terminate the reaction, and centrifuged at 1500 rpm for 5 minutes to obtain a supernatant.
  • the supernatant was completely dried at 60 ° C., dissolved in 50 ⁇ l ethyl acetate, and developed in TLC.
  • the solvent used for the separation conditions of TLC was 50% cyclohexane, 50% ethyl acetate.
  • Testosterone a product appearing on TLC, was identified by UV irradiator at 254 nm, and dihydrotestosterone was confirmed by spraying 10% sulfuric acid.
  • testosterone and dihydrotestosterone sites were cut out and 10 ml of Ultima GoldTM cocktail (PerkinElmer, Massachusetts, USA) was added to the liquid scintillation analyzer (Packard Bioscience, Meriden, USA).
  • the conversion rate of testosterone by 5-alpha reductase was calculated by the following equation.
  • Dermal papilla cells are cells that give hair growth orders in the lower part of the hair follicles below the pores. Therefore, it was tested whether fermented camellia oil promotes the growth of dermal papilla cells.
  • Human dermal papilla cells were used as cell lines used in the experiment.
  • Cell culture was incubated at 37 °C, 5% CO 2 using DMEM medium added with 10% FBS.
  • Cells were dispensed at 1 x 10 5 cells / mL for each well of 96 wells and then incubated for 24 hours. After 24 hours, the medium used for the previous culture was removed, the sample was dissolved in DMSO, diluted with medium so that the final concentration of DMSO was 1%, and the concentration of fermented oil ( ⁇ g / mL) was 37 ° C. and 5% CO 2 , respectively. Each for 24 hours.
  • finasteride was treated with 0.5 ppm.
  • Cell growth rate (%) (absorbance of sample treatment group / absorbance of control group) ⁇ 100
  • the growth and proliferation effect of the dermal papilla cells was excellent at 400 ppm of fermented camellia oil, and the dermal papilla cells were grown by 120 ⁇ 4.5% compared to the control group.
  • 400 ppm of fermented camellia oil was more effective than 104.5 ⁇ 3.3% of 0.5 ppm finasteride.
  • MTT assay was performed to determine the toxicity of Raw 264.7 cells, a mouse-derived macrophage line of fermented camellia oil of the present invention.
  • Toxicity of macrophages was analyzed by MTT [(3- (4,5-dimethyl thiazol-2-yl) -2,5-diphenyl tetrazolium bromide) (Sigma, MO, USA)].
  • Raw264.7 cells were dispensed at 1 ⁇ 10 4 cells / mL for each well of 96 wells and then incubated at 37 ° C., 5% CO 2 for 24 hours. After 24 hours, the medium used for the previous culture was removed, the sample was dissolved in DMSO, diluted with medium so that the final concentration of DMSO was 1%, and the concentration of fermented oil ( ⁇ g / mL) was 37 ° C. and 5% CO 2 , respectively.
  • the experimental animals were rats of 6-week-old Sprague Dawley (SD) strain (Samtako, Korea). These animals did not show any general symptoms at the time of acquisition and during adaptation. Breeding conditions were carried out after setting the temperature 22 ⁇ 2 °C, relative humidity 45 ⁇ 10%, lighting time 12 hours (6 am to 6 pm), solid feed for experimental animals (Samtako, Korea) and water purification system Tap water was used freely.
  • SD Sprague Dawley
  • Tap water was used freely.
  • the experimental group dissolved and administered fermented camellia oil in distilled water
  • the control group administered distilled water were fasted 12 hours before sample administration and used as a single toxic oral dose of normal functional foods.
  • a male clinical subject with alopecia was selected using the fermented camellia oil of the present invention and a simple clinical trial was conducted.
  • Subjects were set up in groups of six for 12 adult males with mild hair loss from 33 to 55 years of age (approximately more than 50 hairs falling off per day and self-aware of their hair loss).
  • One group applied 5 ml of fermented camellia oil to the hair once a day (before bedtime) and wrapped the hair the next day.
  • the other group was placebo group once a day before fermenting camellia oil, 5
  • the ml was applied to the hair for the same period (4 weeks) and the results were observed.
  • the average number of hair loss, visual evaluation, and the individual's personal opinions were selected as the evaluation scale after the head was closed, and evaluated in five stages. . More details are shown in Table 6 below. The overall test results are shown as the average of each score.
  • Clinical trial evaluation index of the present invention Score Visual evaluation Personal opinion Hair loss One weakening weakening increase 2 No change No change No change 3 Slightly improved Slightly improved Slightly reduced 4 Moderate improvement Moderate improvement Usually reduced 5 Much improvement Much improvement Much reduced

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une utilisation d'huile de graines fermentées de Camellia japonica qui présente une teneur élevée en acides gras libres essentiels, et plus particulièrement, un médicament, un complément alimentaire ou un produit cosmétique permettant de prévenir et d'atténuer une hypertrophie bénigne de la prostate et la calvitie masculine, contenant de l'huile de graines fermentées de Camellia japonica utilisée en tant que principe actif, étant donné que l'huile de graines fermentées de Camellia japonica, qui est préparée par fermentation de l'huile de graines de Camellia japonica, est riche en acides gras libres essentiels et présente une remarquable activité inhibitrice de 5-alpha réductase, ce qui permet de prévenir et d'atténuer une hypertrophie bénigne de la prostate et la calvitie masculine. Selon la présente invention, les effets des acides gras essentiels peuvent être maximisés en augmentant la teneur en acides gras essentiels, qui sont isolés de manière à faciliter l'absorption et l'utilisation in vivo, à travers la fermentation indirecte de l'huile de graines de Camellia japonica. De plus, selon la présente invention, l'huile de graines fermentées de Camellia japonica a une activité similaire à celle du finastéride, qui prévient et atténue une hypertrophie bénigne de la prostate et la calvitie masculine en présentant une faible toxicité observée grâce à un essai de toxicité de dose unique et à une évaluation de la cytotoxicité, en ayant comme effet d'abaisser la teneur en dihydrotestostérone par inhibition de la 5-α réductase, en présentant comme effet de restaurer la taille de la prostate à un niveau normal par rapport à une hypertrophie bénigne de la prostate, en favorisant la croissance de cellules du follicule pileux et en présentant comme effet d'atténuer le phénomène de calvitie de patients observé grâce à de simples essais cliniques, et peut ainsi être appliquée, préparée, et vendue comme produit cosmétique, complément alimentaire ou composition pharmaceutique en utilisant une huile naturelle fermentée comprenant de l'huile de graines fermentées de Camellia japonica ayant une efficacité et des effets similaires ou identiques à ceux de produits dérivés du produit naturel.
PCT/KR2015/001925 2014-03-11 2015-02-27 Huile de graines fermentées de camellia japonica inhibant la 5-alpha réductase permettant d'atténuer une hypertrophie bénigne de la prostate et la calvitie Ceased WO2015137652A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2014-0028160 2014-03-11
KR1020140028160A KR101452320B1 (ko) 2014-03-11 2014-03-11 전립선 비대증 및 탈모를 개선하는 ５―알파 환원효소 억제용 발효 동백오일

Publications (1)

Publication Number Publication Date
WO2015137652A1 true WO2015137652A1 (fr) 2015-09-17

Family

ID=51998113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/001925 Ceased WO2015137652A1 (fr) 2014-03-11 2015-02-27 Huile de graines fermentées de camellia japonica inhibant la 5-alpha réductase permettant d'atténuer une hypertrophie bénigne de la prostate et la calvitie

Country Status (2)

Country Link
KR (1) KR101452320B1 (fr)
WO (1) WO2015137652A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111449998A (zh) * 2020-03-25 2020-07-28 广西冠硕科技有限公司 一种植萃防脱生发液及其制备方法
CN118743649A (zh) * 2024-06-04 2024-10-08 广州环亚化妆品科技股份有限公司 一种抑菌、抗氧化的油茶籽发酵物及其制备方法和应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101626319B1 (ko) * 2014-07-15 2016-06-01 주식회사 바이오랜드 동백오일 발효물 또는 그 추출물을 함유하는 모발 성장 촉진 또는 탈모 방지용 조성물 및 그 제조방법
KR102273967B1 (ko) * 2014-10-31 2021-07-08 (주)아모레퍼시픽 인삼씨유를 함유하여 전립선 비대증을 예방 및 치료하는 조성물
KR101662514B1 (ko) 2014-12-05 2016-10-05 충남대학교산학협력단 천연물 추출물을 포함하는 전립선 비대증의 예방 또는 치료용 조성물
KR101711143B1 (ko) * 2015-04-30 2017-02-28 이미선 천연 비누의 제조방법 및 이에 의해 제조된 천연 비누
KR101794771B1 (ko) * 2017-01-19 2017-11-09 (주)코엔바이오 탈모 예방, 발모 촉진 또는 성기능 개선능이 있는 브레비바실러스 루제리 균주 및 이를 포함하는 조성물
KR102145112B1 (ko) * 2018-11-30 2020-08-18 주식회사 벤스랩 높은 탈모개선효과를 지닌 고농도 유리 감마-리놀렌산을 포함하는 효소처리 보라지 오일, 이의 제조방법 및 이를 포함하는 화장료 조성물
KR102508369B1 (ko) 2019-09-09 2023-03-09 (주)리즈바이오텍 산딸기 추출물, 비수리 추출물 및 산사 추출물의 단일 또는 복합 혼합물을 유효성분으로 포함하는 전립선 비대증 예방 또는 치료용 약학적 조성물
KR20210131598A (ko) 2020-04-24 2021-11-03 바이오스펙트럼 주식회사 동백나무 과피 추출물을 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 조성물
KR102471364B1 (ko) * 2021-10-29 2022-11-25 재단법인 전남바이오산업진흥원 압착 추출된 동백씨 오일 및 이의 제조 방법
KR20240105664A (ko) 2022-12-28 2024-07-08 바이오스펙트럼 주식회사 동백나무 과피 추출물 및 백미꽃 추출물을 유효성분으로 포함하는 두피 진정용 화장료 조성물
KR102780319B1 (ko) 2023-01-17 2025-03-12 바이오스펙트럼 주식회사 동백나무 과피 추출물을 유효성분으로 포함하는 두피 개선용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100673837B1 (ko) * 2005-11-25 2007-01-24 고려대학교 산학협력단 1,3-위치 선택성 리파아제와 무위치 선택성 리파아제를이용하여 바이오디젤을 제조하는 방법
JP2009521920A (ja) * 2005-12-28 2009-06-11 ユニバーシティー プトラ マレーシア ジアシルグリセロールの製造方法
JP2011105695A (ja) * 2009-11-13 2011-06-02 Bhn Kk 経口発毛促進剤
KR101238706B1 (ko) * 2012-08-16 2013-03-04 주식회사 내추럴솔루션 섬오가피 추출물을 유효성분으로 함유하는 동백 발효 인퓨즈드오일, 이의 제조방법 및 이를 유효성분으로 함유하는 항산화, 항노화, 항염, 미백, 항주름 또는 항알러지용 화장료 조성물
KR20130023162A (ko) * 2011-08-26 2013-03-07 한국생명공학연구원 발효 식물성 오일 및 이를 포함하는 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040092755A (ko) * 2003-04-29 2004-11-04 주식회사 엘지생활건강 모발 성장 촉진제 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100673837B1 (ko) * 2005-11-25 2007-01-24 고려대학교 산학협력단 1,3-위치 선택성 리파아제와 무위치 선택성 리파아제를이용하여 바이오디젤을 제조하는 방법
JP2009521920A (ja) * 2005-12-28 2009-06-11 ユニバーシティー プトラ マレーシア ジアシルグリセロールの製造方法
JP2011105695A (ja) * 2009-11-13 2011-06-02 Bhn Kk 経口発毛促進剤
KR20130023162A (ko) * 2011-08-26 2013-03-07 한국생명공학연구원 발효 식물성 오일 및 이를 포함하는 조성물
KR101238706B1 (ko) * 2012-08-16 2013-03-04 주식회사 내추럴솔루션 섬오가피 추출물을 유효성분으로 함유하는 동백 발효 인퓨즈드오일, 이의 제조방법 및 이를 유효성분으로 함유하는 항산화, 항노화, 항염, 미백, 항주름 또는 항알러지용 화장료 조성물

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111449998A (zh) * 2020-03-25 2020-07-28 广西冠硕科技有限公司 一种植萃防脱生发液及其制备方法
CN111449998B (zh) * 2020-03-25 2023-09-08 广西冠硕科技有限公司 一种植萃防脱生发液及其制备方法
CN118743649A (zh) * 2024-06-04 2024-10-08 广州环亚化妆品科技股份有限公司 一种抑菌、抗氧化的油茶籽发酵物及其制备方法和应用

Also Published As

Publication number Publication date
KR101452320B1 (ko) 2014-10-22

Similar Documents

Publication Publication Date Title
KR101452320B1 (ko) 전립선 비대증 및 탈모를 개선하는 ５―알파 환원효소 억제용 발효 동백오일
EP2124922B1 (fr) Composition contenant de la rutine et d'acide gras polyinsaturé ayant une activité inhibitrice sur la 5 -réductase
WO2016182225A1 (fr) Composition de prévention de la chute des cheveux et de stimulation de la croissance des cheveux
KR100829728B1 (ko) 봉미초 추출물을 함유하는 피부 외용제 조성물
WO2020218781A1 (fr) Composition fonctionnelle contenant un milieu de culture riche en exosomes dérivé d'une cellule souche immortalisée et un extrait de bourgeon de rose en tant que principes actifs
KR20210009526A (ko) 복합 히아루론산을 함유하는 화장료용 조성물
KR20110134614A (ko) 우방자 발효물을 함유하는 피부외용제 조성물
WO2015111902A9 (fr) Huile végétale fermentée ayant une teneur élevée en acide gras insaturé essentiel libre, et son procédé de préparation
KR101458496B1 (ko) 아위버섯 자실체 추출물 또는 아위버섯 균사체 추출물 또는 아위버섯 균사체 배양액을 함유하는 항염용 피부 외용제 조성물
KR101402193B1 (ko) 아위버섯 자실체 추출물 또는 아위버섯 균사체 추출물 또는 아위버섯 균사체 배양액을 함유하는 피부 미백용 화장료 조성물
WO2024010355A1 (fr) Composition antivieillissement contenant un extrait de lie de vin de gosori
KR101806992B1 (ko) 발효홍삼 추출물을 함유하는 피부세포 사멸방지용 화장료 조성물
WO2019132217A1 (fr) Composition cosmétique comprenant comme principe actif une solution fermentée du fruit de styphnolobium japonicum ou un extrait liquide de celle-ci et destinée à réduire les rides de la peau, et procédé de préparation associé
KR20140081138A (ko) 우장지버섯 자실체 추출물 또는 우장지버섯 균사체 추출물을 함유하는 피부 외용제 조성물
WO2011126189A1 (fr) Composition de prévention de la chute des cheveux et de stimulation de la croissance des cheveux
CN110403840A (zh) 一种具有美白祛斑功效的护肤组合物及其应用和制备方法
JP2010043015A (ja) 花粉荷を含有する酵素阻害剤
KR101580965B1 (ko) 삼색도장버섯 자실체 추출물 또는 삼색도장버섯 균사체 추출물 또는 삼색도장버섯 균사체의 배양액을 함유하는 화장료 조성물 및 피부외용제 조성물
KR20200072108A (ko) 동규자 추출물을 유효성분으로 포함하는 탈모 방지용 화장료 조성물
WO2016056780A1 (fr) Composition pour prévenir la chute des cheveux ou stimuler la pousse des cheveux comprenant un extrait de scutellaria alpina
WO2023059047A1 (fr) Composition pour la prévention ou le traitement de la chute des cheveux, comprenant un extrait de samdachal-jo (millet glutineux de jeju)
KR20140081137A (ko) 곰보버섯 자실체 추출물 또는 곰보버섯 균사체 추출물을 함유하는 피부 외용제 조성물
KR20150065256A (ko) 광나무열매 추출물을 함유하는 화장료 조성물
WO2010150954A1 (fr) Composition médicinale coréenne traditionnelle capable d'améliorer une dermatite atopique par inhibition de tslp
KR102147604B1 (ko) 소듐 서팩틴을 포함하는 탈모 방지 및 발모 촉진용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15761427

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15761427

Country of ref document: EP

Kind code of ref document: A1